文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

癌症干细胞的转录调控:调控因子的阐明和癌症治疗策略。

Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies.

机构信息

Department of Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201900, People's Republic of China.

Shanghai Institute of Precision Medicine, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200125, People's Republic of China.

出版信息

J Exp Clin Cancer Res. 2024 Apr 2;43(1):99. doi: 10.1186/s13046-024-03021-y.


DOI:10.1186/s13046-024-03021-y
PMID:38561775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10986082/
Abstract

Cancer stem cells (CSCs) were first discovered in the 1990s, revealing the mysteries of cancer origin, migration, recurrence and drug-resistance from a new perspective. The expression of pluripotent genes and complex signal regulatory networks are significant features of CSC, also act as core factors to affect the characteristics of CSC. Transcription is a necessary link to regulate the phenotype and potential of CSC, involving chromatin environment, nucleosome occupancy, histone modification, transcription factor (TF) availability and cis-regulatory elements, which suffer from ambient pressure. Especially, the expression and activity of pluripotent TFs are deeply affected by both internal and external factors, which is the foundation of CSC transcriptional regulation in the current research framework. Growing evidence indicates that regulating epigenetic modifications to alter cancer stemness is effective, and some special promoters and enhancers can serve as targets to influence the properties of CSC. Clarifying the factors that regulate CSC transcription will assist us directly target key stem genes and TFs, or hinder CSC transcription through environmental and other related factors, in order to achieve the goal of inhibiting CSC and tumors. This paper comprehensively reviews the traditional aspects of transcriptional regulation, and explores the progress and insights of the impact on CSC transcription and status through tumor microenvironment (TME), hypoxia, metabolism and new meaningful regulatory factors in conjunction with the latest research. Finally, we present opinions on omnidirectional targeting CSCs transcription to eliminate CSCs and address tumor resistance.

摘要

癌症干细胞(CSC)于 20 世纪 90 年代首次被发现,从全新的视角揭示了癌症起源、迁移、复发和耐药的奥秘。多能基因的表达和复杂的信号调控网络是 CSC 的显著特征,也是影响 CSC 特征的核心因素。转录是调节 CSC 表型和潜能的必要环节,涉及染色质环境、核小体占据、组蛋白修饰、转录因子(TF)可用性和顺式调控元件,这些都受到环境压力的影响。特别是,多能 TF 的表达和活性受到内部和外部因素的深刻影响,这是当前研究框架中 CSC 转录调控的基础。越来越多的证据表明,调节表观遗传修饰以改变癌症干性是有效的,一些特殊的启动子和增强子可以作为影响 CSC 特性的靶点。阐明调节 CSC 转录的因素将有助于我们直接针对关键的干性基因和 TF,或通过环境和其他相关因素抑制 CSC 转录,以达到抑制 CSC 和肿瘤的目的。本文全面回顾了转录调控的传统方面,并结合最新研究,探讨了肿瘤微环境(TME)、缺氧、代谢和新的有意义的调控因子对 CSC 转录和状态的影响的进展和见解。最后,我们对全方位靶向 CSCs 转录以消除 CSCs 和解决肿瘤耐药性提出了意见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3340/10986082/2c316df51d6b/13046_2024_3021_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3340/10986082/5e24dbc191ca/13046_2024_3021_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3340/10986082/93df4be6cf00/13046_2024_3021_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3340/10986082/2c316df51d6b/13046_2024_3021_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3340/10986082/5e24dbc191ca/13046_2024_3021_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3340/10986082/93df4be6cf00/13046_2024_3021_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3340/10986082/2c316df51d6b/13046_2024_3021_Fig3_HTML.jpg

相似文献

[1]
Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies.

J Exp Clin Cancer Res. 2024-4-2

[2]
Stem cell programs in cancer initiation, progression, and therapy resistance.

Theranostics. 2020

[3]
Epigenetic Regulation of Inflammatory Cytokine-Induced Epithelial-To-Mesenchymal Cell Transition and Cancer Stem Cell Generation.

Cells. 2019-9-25

[4]
Transcriptional factors targeting in cancer stem cells for tumor modulation.

Semin Cancer Biol. 2023-1

[5]
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy.

Semin Cancer Biol. 2024-5

[6]
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.

Mol Cancer. 2023-10-18

[7]
[Epigenetics in cancer stem cells].

Yi Chuan. 2013-9

[8]
Cancer stem cells (CSCs) in cancer progression and therapy.

J Cell Physiol. 2018-11-11

[9]
Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors.

Int J Oncol. 2010-12

[10]
Bench to Bedside: New Therapeutic Approaches with Extracellular Vesicles and Engineered Biomaterials for Targeting Therapeutic Resistance of Cancer Stem Cells.

ACS Biomater Sci Eng. 2022-11-14

引用本文的文献

[1]
Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors.

Cell Death Dis. 2025-9-1

[2]
Decoding the role of cancer stem cells in digestive tract tumors: Mechanisms and therapeutic implications (Review).

Int J Oncol. 2025-7

[3]
Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.

Front Oncol. 2025-6-6

[4]
OCT4 and MENA immunoprofiling in salivary mucoepidermoid carcinoma.

Diagn Pathol. 2025-5-27

[5]
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances.

Signal Transduct Target Ther. 2025-4-4

[6]
Impact of G1 phase kinetics on the acquisition of stemness in cancer cells: the critical role of cyclin D.

Mol Biol Rep. 2025-2-14

[7]
Insights on Bmi-1 therapeutic targeting in head and neck cancers.

Oncol Res. 2025-1-16

本文引用的文献

[1]
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?

Cancer Metastasis Rev. 2024-3

[2]
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.

Cancer Res Commun. 2023-9-14

[3]
Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.

Int J Mol Sci. 2023-6-21

[4]
Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy.

ACS Nano. 2023-7-25

[5]
YY2-DRP1 Axis Regulates Mitochondrial Fission and Determines Cancer Stem Cell Asymmetric Division.

Adv Sci (Weinh). 2023-8

[6]
Oncogenic Impact of TONSL, a Homologous Recombination Repair Protein at the Replication Fork, in Cancer Stem Cells.

Int J Mol Sci. 2023-5-31

[7]
FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.

BMC Cancer. 2023-6-5

[8]
Therapeutic inhibition of Bmi-1 ablates chemoresistant cancer stem cells in adenoid cystic carcinoma.

Oral Oncol. 2023-7

[9]
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.

Drugs R D. 2023-6

[10]
Combined GSK-3β and MEK inhibitors modulate the stemness and radiotherapy sensitivity of cervical cancer stem cells through the Wnt signaling pathway.

Chem Biol Interact. 2023-8-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索